Tag:

cancer stem cells

Latest Headlines

Latest Headlines

Stem cell factor could improve ovarian cancer prognosis

In a recent study, researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis.

Stem cell factor could improve ovarian cancer prognosis

In a recent study, researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis.

Biomarker spotted for colon cancer stem cells

Kyoto University scientists say they've successfully linked a biomarker to colon cancer stem cells in a mouse study, offering another potential way to develop a targeted cancer treatment with minimal side effects.

Biomarker spotted for colon cancer stem cells

Kyoto University scientists say they've successfully linked a biomarker to colon cancer stem cells in a mouse study, offering another potential way to develop a targeted cancer treatment with minimal side effects.

Stemline delays IPO to fund cancer drugs

Stemline Therapeutics delayed its initial public offering this week, as another biotech faces a rocky road from private to public status. The oncology drug specialist planned to raise $42 million in an IPO this week at a price of $11 to $13 per share, the Nasdaq reported Tuesday, selling itself as a leader in the development of drugs that home in on cancer stem cells that are implicated in cancer recurrence.

OncoMed offers $115M IPO bet on cancer stem cell work

A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.

Company 'insiders' left with 43% of Verastem's shares

Anyone trying to understand what it takes to pull off a successful biotech IPO these days should check out a series of 13Ds Verastem's ($VSTM) insiders filed last month. In the days after...

Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout

Boston Biomedical's focus on targeting cancer stem cells has paid off.

Fledgling Verastem outlines investor strategy behind high-risk $50M IPO

As today's report on 2011's small class of biotech IPOs makes clear, this is a lousy time for a drug developer to go public--even if it has a compelling late-stage program to boast about. But

Verastem snags $32M for drugs against cancer stem cells

The young field of cancer stem cells has some new financial firepower behind it. Start-up Verastem has closed a $32 million Series B round of financing with plans to advance its first drug against
'